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3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) lyase deﬁciency is an inborn error of metabolism characterized by
impairment of ketogenesis and leucine catabolism resulting in an organic acidopathy. In 1994, a case of dilated cardiomyopathy
and fatal arrhythmia was reported in a 7-month-old infant. We report a case of dilated cardiomyopathy in association with HMG
CoA lyase deﬁciency in a 23-year-old man with the acute presentation of heart failure. To our knowledge, this is the ﬁrst case
reported in an adult.
Copyright © 2009 Alexander A. C. Leung et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Described in 1976, 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG CoA) lyase deﬁciency is a rare autosomal recessively
inherited inborn error of metabolism characterized by
impairment of ketogenesis and leucine catabolism resulting
inattacksofmetabolicacidosis,hypoglycemia(withoutketo-
sis), and a characteristic pattern of elevated urinary organic
acids: 3-hydroxy-3-methylglutaric, 3-methylgutaconic, 3-
methylglutaric, and 3-hydroxyisovaleric acids. Patients typ-
ically present within the ﬁrst year of life [1]. This condi-
tion has been associated with hepatomegaly, pancreatitis,
seizures, and hyperammonemia. In 1994, Gibson et al.
reportedafatalcaseofdilatedcardiomyopathyina7-month-
old infant with HMG CoA lyase deﬁciency [2]. We report the
ﬁrst case of dilated cardiomyopathy in an adult with HMG
CoA lyase deﬁciency.
2. Case Presentation
A 23-year-old man with HMG CoA lyase deﬁciency pre-
sented with two months of exertional dyspnea and cough
with progressive malaise and lethargy. He denied any weight
gain, swelling, orthopnea, or paroxysmal nocturnal dyspnea.
He was diagnosed at age 9 months and is the only child
of fourth cousin parents of Portugese ancestry. There is no
family history of inherited metabolic disease, heart disease,
or sudden unexplained deaths. He was initially treated with
levo-carnitine, but had stopped taking it for 5 years as he
reported unpleasant “ﬁshy” body and urine odour.
Examination revealed a blood pressure of 115/87mmHg,
a regular heart rate of 122 beats per minute, respiratory rate
30 breaths per minute on room air. The jugular venous pul-
sation was elevated above the angle of the jaw. His apex was
laterally displaced. A normal S1, physiologically split S2, and
S3 were auscultated. The remainder of the cardiovascular,
respiratory, abdominal, musculoskeletal, neurological, and
dermatological examination was unremarkable.
Investigations revealed a normal complete blood count.
Brain natriuretic peptide was elevated at 2067pg/mL
and troponin I levels were undetectable. Urinary organic
acid analysis by mass spectrometry detected massive
amounts of 3-hydroxy-3-methylglutaric and methylgluta-
conic acids. Serum total free carnitine was 11µmol/L
(normal 16–66µmol/L), total carnitine 17µmol/L( n o r m a l2 Case Reports in Medicine
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Figure 1: Biochemical pathways illustrating ketogenesis through the metabolism of fatty acids and leucine.
25–88µmol/L), and beta-hydroxybutyrate was undetectable.
Creatinine kinase and thyroid stimulating hormone were
normal. Viral studies were negative. Electrocardiogram
showed sinus tachycardia. Chest radiograph showed an
increased cardiothoracic ratio, a small left pleural eﬀusion,
and normal pulmonary vascularity and interstitial markings.
Cardiac magnetic resonance (CMR) imaging revealed severe
left ventricular enlargement (left ventricular end diastolic
volume of 354mL) with an ejection fraction of 15% and an
apical thrombus, severe right ventricular dysfunction, severe
biatrial enlargement, but no valvular disease. There was no
evidence of myocarditis [3].
The diagnosis of heart failure secondary to dilated
cardiomyopathy was made in association with HMG CoA
lyase deﬁciency and carnitine deﬁciency. He was treated
with carvedilol, ramipril, furosemide, spironolactone, and
warfarin. A dietary treatment with moderate protein restric-
tion, avoidance of high-fat, and increasing carbohydrate
consumption to avoid fasting was reinforced. Levo-carnitine
was restarted. After 10-months of follow-up, he had New
York Heart Association (NYHA) class I symptoms, but no
signiﬁcant recovery of left ventricular function.
3. Discussion
It has been previously reported that a 7-month old boy with
HMG CoA lyase deﬁciency manifested a fatal arrhythmia
associated with a dilated cardiomyopathy [2]. Autopsy
conﬁrmed the presence of a dilated cardiomyopathy with
vacuolar cytoplasmic changes in the absence of myocarditis,
and negative viral serologies and cultures. In our patient,
myocarditis was excluded using CMR [3, 4]. We postulate
that his cardiomyopathy resulted from impaired ketogenesis,
intracellular fatty acid accumulation, and secondary carni-
tine deﬁciency.
HMG CoA lyase catalyzes the last step in the catabolism
of leucine and free fatty acids in ketogenesis (Figure 1).
Under normal conditions, ketones are a minor energy
substrate for the myocardium [5, 6]. More signiﬁcant ketone
utilization occurs during times of starvation, in heart failure,
andwithhigh-fatdiets.InthesettingofHMGCoAlyasedeﬁ-
ciency,deprivationofthisenergysubstratemayconsequently
contribute to myocardial dysfunction [5]. Ketone bodies,
derived from beta-oxidation of free fatty acids, supply 60–
90% of the total myocardial energy requirements, with the
remaining energy needs met primarily by glucose [5]. Phys-
iologically, fatty acid uptake is regulated by mitochondrial
utilization, thereby preventing intracellular accumulation.
In HMG CoA lyase deﬁciency, this regulative mechanism
is impaired, and subsequent myocardial cytotoxicity and
dysfunction result as a result of intracellular fatty acid
accumulation [6].
Carnitine is essential for normal myocardial function
[5, 7]. Fatty acids are transported from the cytosol into the
mitochondria for beta-oxidation via the carnitine palmi-
toyltransferase shuttle system. In addition to its role in
fatty acid transport, carnitine also serves as a free radical
scavenger, and a cofactor in the oxidation of long-chain
fatty acids, the metabolism of branched-chain amino acids,
and nuclear transcription [5]. In HMG CoA lyase deﬁency,
secondary carnitine deﬁciency results from esteriﬁcation of
free carnitine to 3-methylglutarylcarnitine. Levo-carnitine
has been reported to attenuate left ventricular dilatation, and
improve survival in patients with dilated cardiomyopathy
and NYHA class III-IV symptoms [7]. Although our patient
symptomatically improved with medical therapy and levo-
carnitine supplementation, no recovery of left ventricular
function was noted after 10 months of follow-up.
While the majority of patients with HMG CoA lyase
deﬁciency present within the ﬁrst year of life, it may rarely
present during adulthood [1]. Adult survivors are felt to
manifest a milder phenotype, and associated complications
may therefore go unrecognized. Although a direct causal
relationship between HMG CoA lyase deﬁciency and dilated
cardiomyopathy has yet to be established, we provide a
biochemical basis for our hypothesis: impaired ketogenesis,
intracellular fatty acid accumulation, and secondary carni-
tine deﬁciency. To our knowledge, we report the ﬁrst case ofCase Reports in Medicine 3
a dilated cardiomyopathy associated with HMG CoA lyase
deﬁciency in adulthood. With report of this case, it is hoped
that more conﬁrmatory case reports would be forthcoming.
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